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ortic Stenosis:
t Is a Hot Topic
he Link to Coronary Artery Disease*
lase A. Carabello, MD, FACC
ouston, Texas
or the past 60 years the primary focus of our attention in
ortic stenosis (AS) has been on the severity of left ventric-
lar outflow obstruction as it related to symptoms, left
entricular function, longevity, and the proper timing of
alve replacement. In developed nations rheumatic fever
aned as a cause of AS, and until 15 years ago the most
ommon cause of AS was classified as “calcific degeneration”—
hatever that meant. Then Otto et al. (1) called our
ttention to the similarities between the plaque of coronary
therosclerosis and the initial lesion of AS. Otto et al. (2)
lso noted an increased risk for patients with aortic sclerosis.
See page 758
ecause aortic sclerosis imparts almost no hemodynamic
onsequences of its own, it seemed likely that aortic sclerosis
as a marker for the co-presence of coronary artery disease
CAD) that in turn was the cause of increased mortality (3).
ubsequently, several studies found commonality between
he risk factors for AS and CAD, especially with regard to
ipid abnormalities (4–8). These observations were tested in
t least 2 animal models that confirmed a role for lipids in
ausing AS. Rabbits fed a high-cholesterol, high-vitamin D
iet developed AS (9), as did mice deficient in low-density
ipoprotein (LDL) receptors (10). And although there are
onflicting data regarding the effectiveness of statins (the
rinciple therapy for the prevention of the adverse effects of
AD), in preventing the progression of AS (11) the data
aken as a whole suggest that statins do have a role in
etarding the worsening of AS (12–15), again suggesting an
S–CAD link. In addition, aortic atherosclerosis and AS
re often present in the same patients (16), further strength-
ning the argument.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.d
From the Department of Medicine, Baylor College of Medicine, and the Veterans
ffairs Medical Center, Houston, Texas.During this period of evolution in our understanding of
he etiology of AS, there was also marked advancement in
ur understanding of CAD leading to the recognition that
his disease was inflammatory in nature and that markers of
nflammation added important negative prognostic infor-
ation over and above the traditional lipid markers (17). Of
nterest, thermal examination of CAD plaques found some
o be “hot” with temperatures increasing in a gradation from
atients with stable angina to those with acute coronary
yndromes to patients suffering a myocardial infarction (18).
hermal heterogeneity was also found in carotid endarter-
ctomy specimens (19).
Perhaps then, it is not so surprising that in this issue of
he Journal, Toutouzas et al. (20) found increased temper-
ture variability in the valves of patients with AS. Hetero-
eneous increases in plaque temperature corresponded with
ther evidence of inflammation, including lymphocyte in-
ltration, calcium deposition, the presence of tissue necrosis
actor-, and interleukin-6. Virtually none of these findings
xtended to valves from patients with aortic insufficiency
here valve pathology is quite different and not thought to
e atherosclerotic. Thus, this study brings the relationship
f AS to CAD and other forms of atherosclerosis yet closer
nd makes it even more interesting. But why then do only
pproximately one-half of the patients with severe AS also
ave severe CAD? Does this discrepancy indicate that the 2
onditions also have major differences? Perhaps yes, perhaps
o. One could also ask: Why do some patients with severe
eft anterior descending artery (LAD) disease have angio-
raphically pristine circumflex and right coronary arteries?
r why do some patients with severe peripheral vascular
isease have no angiographically detectable CAD at all? Or
hy is the internal mammary artery, of similar size to the
AD, almost always free from atherosclerosis? Clearly many
nswers are not yet in.
hy Do Patients Develop AS?
he answer to the question posed is obviously unknown,
ecause we have no unifying hypothesis for atherosclerosis
n general, but there are some intriguing hints. First, there
s much circumstantial evidence that hemodynamic stress
lays a role. Calcium deposition occurs primarily on the
ortic side of the valve where turbulence and shear stresses
re highest. Second, AS occurs sooner and more often in
atients with bicuspid aortic valves. Presumably such valves
ave poorer hemodynamic characteristics than normal tri-
uspid aortic valves. It should be noted that bicuspid aortic
alves are also associated with abnormalities in the
OTCH 1 gene that also regulates calcium deposition
21,22). Thus, bicuspid aortic valve could lead to AS through
different mechanisms, hemodynamic stress and genetic
ysregulation of bone-forming pathways. Third, although
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August 26, 2008:764–6 Editorial Commentften depicted as symmetrical, tricuspid aortic valves rarely
re (23). In fact it is unusual for all 3 leaflets to have the
ame area, and therefore stresses on the leaflets vary (24). It
s possible that leaflet areas of higher stress are where AS
egins. Admittedly this would be a very difficult hypothesis
o test. An in vivo stress analysis would have to be
erformed when the valve was normal then followed until
S began to develop. But if most aortic valves have unequal
tresses placed upon them, why don’t most people develop
S? It is probable that stress is only the first step in the
athophysiology of AS, and in the absence of other down-
tream abnormalities, AS does not occur. It is likely that the
ext step involves LDL. High LDL levels are associated
ith endothelial dysfunction, nitric oxide deficiency, and
ncreased superoxide activity in AS (10,25–27). Thus, me-
hanical stress combined with factors that promote oxidative
tress support an inflammatory cascade leading to further
alve disruption ultimately activating pathways leading to
alcium deposition and bone formation (28). In this regard
hetty et al. (29) demonstrated deficient osteoprotegerin, a
rotein that promotes osteoclast activity in severely calcified
ortic allografts. Osteoclasitc inactivity could then potenti-
te bone formation (29). Furthermore, Rajamannan et al.
30) found that Watanabe rabbits, deficient in LDL recep-
ors, fed a high cholesterol diet had up-regulation of Lrp5,
n LDL-related receptor that can activate bone formation.
Thus, there might be a stream of biological events
tarting with hemodynamic stress, incorporating LDL that
auses oxidative stress, leading to inflammation and calcifi-
ation and bone formation, culminating in severe AS. If so,
hen there are obviously a host of elements in this cascade
hat could be targeted for the prevention or retardation of
rogression of the disease.
We have come a long way in our understanding of AS
rom the time of my fellowship when we called it a
egenerative disease—code for “we don’t know what’s going
n here”—to our current understanding of the disease as an
ctive inflammatory process with much in common with
AD. We have a long way to go, but wouldn’t it be exciting
f both diseases shed light on each other, forming a unifying
echanism for how atherosclerosis develops.
eprint requests and correspondence: Dr. Blase A. Carabello,
eterans Affairs Medical Center, Medical Service (111), 2002
olcombe Boulevard, Houston, Texas 77030. E-mail: blaseanthony.
arabello@med.va.gov.
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